Drug Trial Radar · NCT07579884
To Evaluate the Safety and Efficacy of RP902 Tablets
Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
360
Planned (sponsor's estimate)
Start
Jul 14, 2026
Primary completion
May 2029
Study completion May 2031
Sponsor
- Lead sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the preliminary efficacy of RP902 Tablets in participants with Alzheimer's disease (AD)-derived mild cognitive impairment (MCI) and provide a design basis for the Phase III study. This Phase II study plans to enroll 360 participants and will be conducted at approximately 50 sites in China. The study consists of a Screening Period (up to 4 weeks) and a double-blind treatment period (48 weeks). After completing the 48-week double-blind treatment period, participants may choose to continue into an extension treatment period (96 weeks) or undergo safety follow-up (4 weeks after the last dose).
Conditions
- Mild Cognitive Impairment (MCI)
Interventions
RP902Drug
The participants will receive RP902
PlaceboDrug
The participants will receive placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Dementia Rating Scale - Sum of BoxesTime frame: Week 48
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Xuanwu Hospital Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.